Search

Displaying results 2041 - 2050 of 6949 in total
  1. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005

    Mixtures: Multivitamins and Minerals for Young Women
  2. Drug

    Chlorquinaldol

    go.drugbank.com/drugs/DB13306
    Approved

    Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]

  3. Drug

    Cinoxacin

    go.drugbank.com/drugs/DB00827
    ApprovedWithdrawn

    Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Polihexanide

    go.drugbank.com/drugs/DB12277
    ApprovedInvestigational

    Polihexanide, also known as polyhexamethylene biguanide (PHMB), is a broad-spectrum antimicrobial polymer primarily used for topical antisepsis and wound management. … [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite.

  5. Drug

    Neon

    go.drugbank.com/drugs/DB11589
    Approved

    Neon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test.

  6. Drug

    Ivacaftor

    go.drugbank.com/drugs/DB08820
    ApprovedInvestigational

    [L6841] Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF. … Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals.

  7. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

    Categories: Prostacyclin Receptor Agonist, Prostacyclin Receptor Agonists
  8. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia. … Olezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  9. Drug

    Pramipexole

    go.drugbank.com/drugs/DB00413
    ApprovedInvestigational

    In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS) [A176873].

    Categories: Nonergot-derivative Dopamine Receptor Agonists
  10. Target

    Serotonin Receptors

    go.drugbank.com/bio_entities/BE0004862
    TargetHumans

    Receptor for lasmiditan, a drug for the treatment of acute migraine (PubMed:34239069). … G protein-coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:10452531, PubMed:1565658, PubMed:1652050, PubMed:33762731).

    Polypeptides: 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1BSynonyms: Serotonin receptor 1A, Serotonin receptor 1B